Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1998 2
2000 3
2001 1
2005 1
2006 2
2009 1
2014 1
2015 4
2016 2
2018 2
2019 3
2022 1
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Pregnancy and radiation.
Fenig E, Mishaeli M, Kalish Y, Lishner M. Fenig E, et al. Among authors: mishaeli m. Cancer Treat Rev. 2001 Feb;27(1):1-7. doi: 10.1053/ctrv.2000.0193. Cancer Treat Rev. 2001. PMID: 11237773 Review.
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
Moskovitz M, Dudnik E, Shamai S, Rotenberg Y, Popovich-Hadari N, Wollner M, Zer A, Gottfried M, Mishaeli M, Rosenberg SK, Onn A, Merimsky O, Urban D, Peled N, Maimon N, Bar J. Moskovitz M, et al. Among authors: mishaeli m. Oncologist. 2022 Feb 3;27(1):e76-e84. doi: 10.1093/oncolo/oyab005. Oncologist. 2022. PMID: 35305096 Free PMC article.
[THE CURRENT APPROACH TO ADVANCED LUNG CANCER].
Gottfried M, Keizman D, Mishaeli M, Maimon Rabinovich N. Gottfried M, et al. Among authors: mishaeli m. Harefuah. 2015 Aug;154(8):521-4, 539-40. Harefuah. 2015. PMID: 26480619 Review. Hebrew.
Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I, Goshen-Lago T, Sternschuss M, Morgenstern S, Geva R, Beny A, Dror Y, Steiner M, Hubert A, Idelevich E, Shulman K, Mishaeli M, Man S, Liebermann N, Soussan-Gutman L, Brenner B. Ben-Aharon I, et al. Among authors: mishaeli m. Oncologist. 2019 Aug;24(8):e696-e701. doi: 10.1634/theoncologist.2018-0351. Epub 2019 Feb 12. Oncologist. 2019. PMID: 30755502 Free PMC article.
Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data.
Brenner B, Shulman K, Hubert A, Man S, Geva R, Ben-Aharon I, Fennig S, Mishaeli M, Yarom N, Bar-Sela G, Brenner R, Shai A, Baehner FL, Russell C, Soussan-Gutman L, Voet H, Bareket-Samish A, Liebermann N. Brenner B, et al. Among authors: mishaeli m. ESMO Open. 2024 Aug;9(8):103648. doi: 10.1016/j.esmoop.2024.103648. Epub 2024 Aug 12. ESMO Open. 2024. PMID: 39137478 Free PMC article.
A comparison of two dose regimens in pancreatic cancer.
Figer A, Sadikov E, Mishaeli M, Koren R, Gal R, Levin I, Klein B. Figer A, et al. Among authors: mishaeli m. J Chemother. 2000 Oct;12(5):442-5. doi: 10.1179/joc.2000.12.5.442. J Chemother. 2000. PMID: 11128566 Clinical Trial.
25 results